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Abstract
Methotrexate (MTX) has been formulated in nano and micro-emulsions,
nominally to address its poor solubility and off-target effects. Nanoformulated MTX is
universally reported to be a more efficacious anti-cancer agent than direct-dissolved drug;
however, these investigations generally fail to screen for in vivo toxicity. This study aims
to remedy this oversight. MTX was formulated as a standard Pluronic oil-in-water
microemulsion with good drug encapsulation efficiency (73.0 % ± 8.4). Preliminary in
vitro free radical scavenging studies found that formulation reduces drug oxidation fourfold. The toxic effects of formulated and unformulated MTX were investigated in a
Wistar rat model. Rats received 0.05 mg/kg MTX as either the microemulsion or directly
dissolved in phosphate-buffered saline. A drug-free microemulsion, PBS solution, and
saline solution were used as controls. After 28 days, serum levels of enzymes indicative
of kidney and liver damage were quantified. Significantly higher serum liver, and serum
kidney enzymes were observed in the rats that received the directly dissolved MTX drug
(P<0.05) compared to those who received the encapsulated form. Following sacrifice, the
levels of catalase and superoxide dismutase (SOD) were significantly lower and the level
of malondialdehyde higher, in rats who received either form of MTX relative to untreated
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controls. However, the SOD levels were lower in those who received the microemulsion
than those who received free MTX. Histology supported the observation that the
microemulsion formulation caused no gross structural toxicity to the liver, unlike the free
drug. Although toxicity was reduced compared to the free drug, the microemulsion still
caused damage to the kidneys. This organ-specific toxicity is consistent with the mode of
clearance of the drug. This data demonstrates that the toxicity of formulated drugs must
be considered when discussing the relative merits of formulations: encapsulation always
improves efficacy but may not always improve safety.

Keywords: Pluronic, dynamic light scattering, microemulsion, percolation, Antioxidant
activity, DPPH, release rate, liver, kidney, liver enzymes, histopathology

Introduction
Microemulsions comprising non-ionic surfactants are promising drug-delivery
nanocarriers as their encapsulation of pharmaceuticals protects the drugs from
physiological degradation, while also assisting with solubility and providing control over
the pharmacokinetics of release.[1-6] However, many factors must be considered to
ensure appropriate encapsulation and release of a specific drug, including the selection of
the oil, surfactant, and co-surfactant.[1-6] In biomedicine, the non-ionic Pluronics, a
polymeric surfactant triblock copolymer comprising poly(propylene oxide) terminated
with poly(ethylene oxide), is commercially available in a very broad range of
compositions, has effective solubilization capacity, sustained release profiles, and good
biocompatibility.[1, 2, 7] Most importantly, the Pluronics are already approved for use in
both pharmaceutical formulations and medical devices.[1, 2] Pluronic-based
microemulsions provide superior colloidal stability compared to those stabilized with
classical ionic surfactants, preventing nanoparticle aggregation. F-127, a Pluronic
surfactant produced by BASF is a particularly well studied system partially due to its
stimuli-responsive behaviour, gelating above 10 ºC at high concentrations.[8, 9]
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Figure 1. Chemical structure of Pluronic F127 (left) and MTX (right)
Methotrexate (MTX), a competitive dihydrofolate reductase inhibitor, was one
of the first chemotherapeutics on the market, and is still clinically deployed to treat breast,
lung, and head and neck cancers.[10] In addition, patients treated with MTX also show a
reduced risk of cardiovascular disease-related hospitalization and death.[11] MTX is also
used to treat rheumatoid arthritis, where it likely acts through enhancing adenosine
levels.[12] Although inhibiting folate formation increases the risk of systemic oxidative
damage, the MTX molecule itself inhibits the formation of reactive oxygen species by
directly removing superoxide anions. This allows it to scavenge lipid peroxidation byproducts, and diminishes inflammation and oxidative damage.[13, 14] However, the
dosage of MTX must be carefully controlled, especially in patients with chronic renal
impairment,

as

it

is

highly

nephrotoxic,

and

leads

to

leukopenia

and

immunosuppression.[10, 13, 15, 16]
Reducing the impact of these off-target effects has been a focus of recent effort as
MTX itself has a long track record of efficacy. Complicating matters, MTX is a poorly
lipid-soluble drug and its water-insolubility makes delivery challenging. Microemulsive
dispersions increase bioavailability, and by sequestering the drug, reduce its side
effects.[17, 18] In an early example, Karasulu et al. designed a microemulsion of MTX
to evaluate its in vitro suppressive effects on MCF-7 human breast cancer cells.[19] The
team employed soybean oil, a mixture of Cremophore EL and Span 80, isopropyl alcohol
and 0.2 N NaOH respectively as the oil phase, surfactants, co-surfactant and the aqueous
phase. More recently, Amarji and colleagues, interested in psoriasis therapies, used a
microemulsion comprising a polysorbate 80 surfactant, phospholipon 90G and ethanol as
co-surfactants, and isopropyl palmitate as the oil, using an analysis of an experimentallyderived pseudo-ternary phase diagram to identify appropriate ratios. They characterized
the in vitro release kinetics, ex vivo permeation and drug distribution of their
microemulsion. [18]
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Pluronics have seen some use in MTX formulation, although normally as a bulk
hydrogel rather than as part of a colloidal solution.[9] The amphiphilicity of MTX that
make it poorly soluble in both hydrophobic and hydrophilic environments do limit its
loading as the drug tends to sit at the interface between the particle and water. This
property makes small nanoparticles with high surface area a useful system for its
formulation.[20, 21]
A recent study by Prakash and coworkers used a hydrogel formed from F-127 (2022% w/v) in water to deliver MTX as an injectable gel; however, as F-127 is not
metabolized, this high level of loading is non-ideal.[22] Pluta and Karolewicz formulated
similar MTX-F127-based hydrogels for potential direct injection into tumours, although
they only studied the release kinetics and rheology of the material,[23] as did Lu and Jun
in a similar F-127 hydrogel.[24] Venkatesh and co-workers likewise studied a potential
MTX-F127 hydrogel formulation for proposed use to treat rheumatoid arthritis, and
showed that the formulation reduced inflammation in a mouse model.[22, 25, 26]
In the earliest example of nanoparticle MTX formulation, Law and Lin prepared
a microsphere emulsion using bovine serum albumin as the core and Pluronic F68 as an
emulsifier. The group showed that formulation slowed MTX release in an animal
model.[27] Abdelbary and Haider studied the growth inhibition on cancer cell lines of
F127-MTX nanostructured lipid carriers with diameters of 250-350 nm with various high
concentrations of MTX.[28] The Sha group prepared a 22 nm mixed micelle consisting
of both F127 and the more hydrophobic P105 to physically encapsulate MTX. This
formulation showed good efficacy against a human cancer xenografted into a murine
model.[29] The Sha group followed up this report with a covalently-immobilized
Pluronic-MTX conjugate that they formulated into micellular nanoparticles. The material
also showed efficacy in a patient-derived xenograft mouse model. However, in neither
study was the toxicity of the formulations investigated.[30] Gao and Jiang showed that
nanoparticles employing Pluronic F68 as an emulsifier were effective at transporting
MTX across the blood-brain barrier.[31] The Zhang group at Liaoning used a
nanoparticle derived from a physical mixture of a Pluronic shell on a chitosan core to
deliver MTX into cancer cells and examined intracellular release. It demonstrated higher
efficacy than the free drug.[32] Katare and co-authors developed a simple synthesis of a
lipid-polymer nanoparticle using F-87 as the Pluronic. This formulation showed excellent
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entrapment efficiency and promising steady release kinetics with a moderate initial burst
release of the drug.[33]
Ren and colleagues formed a Pluronic-drug conjugate using an ester linkage,
attaching MTX to a Pluronic polymer of undisclosed molecular weight. The ester
hydrolyses slowly to release the drug under physiological conditions.[34] While we were
preparing this manuscript, in an effort to better control drug release, Loureiro and
coworkers formulated a nanoparticle where MTX was immobilized on the P407 through
a comparably stable amide bond. These systems showed slower release in the presence
of enzymes necessary to cleave the linkage, and also showed higher efficacy against
cancer cell lines than the free MTX.[35]
Building on all these results, Meshkini and Oveisi immobilized F127 to a
mesoporous zinc hydroxyapatite and then to a covalently conjugated MTX to the free
terminus of the polymer to make a hard nanoparticle. The amide bond between the drug
and the polymer was selected to be enzymatically cleavable at low tumour-relevant pH.
Like the other results described here, they were effective against cancer cell lines.[36]
What most studies have overlooked to date is the toxicity of MTX; the efficacy of
nanoformulated MTX therapy is not in doubt, but one of the goals of a formulation is to
reduce the side effects and the toxic profile of the drug. As part of our program in targeted
drug delivery, we wish to emphasize the need to consider systemic toxicity early in the
discovery process as an essential endpoint.[37] Consequently, using a Pluronic
microemulsion related to those discussed above, we needed to investigate the safety of
physically-encapsulated MTX in a mammalian model.

2. Material and Methods
2.1 Materials
Pluronic F127 was purchased from BASF Inc. (Mount Olive, NJ). MTX, sodium
caprylate, sodium deconoate, ethyl butyrate and 2,2-diphenyl-1-picrylhydrazyl (DPPH)
were purchased from Sigma Chemical Co. (St. Louis, MO). Potassium phosphate
monobasic, potassium phosphate dibasic, sodium chloride, and potassium chloride which
were purchased from Fisher Scientific Inc. (Suwanee, GA). Doubly distilled, deionized
Millipore water was used. All chemicals were used as received with no further
purification.
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2.2 Preparation of MTX-containing F127 nanometer-sized microemulsions
Pluronic oil-in-water microemulsions (10 mL samples) encapsulating MTX were
prepared by vigorously stirring the required amounts of fatty acid sodium caprylate (SC),
phosphate buffered saline (PBS at pH 7.4), and at a fixed oil-to-surfactant molar ratio
(Ow = [ethyl butyrate]/[Pluronic] = 1), and MTX-to-pluronic molar ratio of
Z=[MTX]/[F127]=0.23. This is according to the protocol developed by Varshney and
coworkers.[6] The MTX was introduced by being pre-dissolved in the ester. Once
formed, these Pluronic microemulsions were diluted with PBS to obtain the desired mass
fraction of droplets (MFD). All operations were conducted at room temperature.

2.3

Dynamic

Light

Scattering

(DLS)

characterization

of

drug-loaded

microemulsions

DLS characterization was conducted on an ALV-5000F (ALV-GmbH, Germany)
Compact Goniometer System under vertically polarized incident light (λ = 488 nm, 2W)
supplied by a diode pumped Nd:YAG solid-state laser (Coherent Inc., CA) combined
with an ALV SP-86 digital correlator with a sampling time of 25 ns to 100 ms.
Measurements were made at an angle of θ = 90° to the incident beam. The intensity scale
was calibrated against scattering from toluene. Prior to analysis, solutions were filtered
through Millipore Millex filters (Triton free, 0.22 μm porosity) directly into cleaned
scattering cells and allowed to equilibrate at the required temperature for 10 min before
measurement. Each experiment was repeated at least three times. Sampling time was 510 min as required to obtain a fitted correlation function.

2.4. Determination of the entrapment efficiency (EE)
The protocol was adapted from standard published approaches.[38-40] MTX
concentration was determined spectrophotometrically using a UV-Vis spectrophotometer
(Agilent Technologies, Cary 60, USA) at a wavelength of 320 nm. Briefly, the spectrum
of MTX was recorded between 200 and 700 nm by a UV-VIS Spectrophotometer to
determine the characteristic peaks of MTX. Our MTX solution in PBS pH 7.4 had two
characteristic peaks at 290 and 320 nm. We chose 320 nm to avoid interfering of
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polymeric backbones with absorption of free MTX. MTX was quantified against a
calibration curve prepared from fresh MTX solutions.
After synthesis, the microemulsions were centrifuged for 20 min at 15000 rpm
(model 5415D, Eppendorf, Germany) to separate the free MTX in the supernatant from
the nanodroplets [38, 40-42], followed by filtration with 0.22 m filters. The MTX
content of the supernatant was quantified at 320 nm. The encapsulation efficiency (EE%)
was calculated as the difference between the total MTX content in the microemulsion
(430 μg/mL) and the free MTX content obtained from the supernatant (Equation 1):

𝐸𝐸% =

𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 𝑜𝑓 𝑀𝑇𝑋−𝐹𝑟𝑒𝑒 𝑀𝑇𝑋
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 𝑜𝑓 𝑀𝑇𝑋

× 100

(1)

2.5. Antioxidant activity of oil-in-water F127 microemulsions

The interaction rate of the DPPH free radical with bulk and microemulsion forms
of MTX was measured as an indicator of the rate of drug release. The absorbance of
methanolic solutions including 1 ml of various forms of MTX (400 µg/ml) and 4 ml of
DPPH (0.004% w/v) was read every 5 min for 30 min at 517 nm. A graph of inhibition
percentage (([absorbance of blank – absorbance of sample] / absorbance of blank) × 100)
vs time was plotted. The slope of the straight-line equations was considered as the release
rate.[5] All tests were repeated three times and the results were expressed as the average
of three independent experiments.

2.6. Animal studies
All animal treatments were carried out in a humane fashion in compliance with
both institutional (University of Zabol) and the NIH guideline for Care and Use of
Animals (NIH publication No 85-23, revised 1996).
In the current experimental study, fifty male adult rats (Wistar breed), were
obtained from the laboratory animal centre of University of Zabol and were divided into
five groups. The first group (control group) received normal saline for four weeks; the
second group received the PBS vehicle alone; the third group received the microemulsion
without the presence of MTX; the fourth group received an unformulated 0.05 mg/kg
dose of MTX in PBS; and the fifth group received the microemulsion formulated MTX
with a dose of 0.05 mg/kg. Animals were kept at standard conditions 20-23 °C and 12 (h)
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light/dark cycles and were fed a standard laboratory diet (Javaneh-Khorasan, Iran). After
28 days, the rats were anesthetized, and blood samples were collected by heart puncture
and immediately centrifuged (3000 rpm for 5 min) in order to separate the serum. The
serum samples were immediately frozen at -80 °C. After euthanasia, liver specimens were
carefully removed and preserved in formalin until examined.

2.7. Determination of serum biochemical parameters and statistical analysis
The activity of catalase in liver tissues was assayed by the Aebi method.[43] This
method was based on measuring the rate of decomposition of H2O2 at 240 nm using a
commercial spectrophotometer (UNICO UV/VIS- 2100 Spectrophotometer). In addition,
the hepatic superoxide dismutase (SOD) activity was assayed based on the method of
Kakkar.[44]
The liver malondialdehyde levels, a marker of lipid peroxidation, was assayed
spectrophotometrically at 532 nm according the method of Okhawa. The Okhawa method
is based on the reaction between 2-thiobarbituric acid (TBA) and malondialdehyde.[45]
Commercial kits (Pars Azmoon. Co., Tehran, Iran) were used to determine the
serum levels of AST, ALT, BUN and creatinine. All the serum biochemical parameters
were measured in the biochemistry laboratory of University of Zabol using the Selectra
Pro M auto analyser, (Vital Scientific, SpanNeren, Netherlands).
Statistical analysis was conducted using the SPSS software (version 20.0).
Multiple comparisons between the experimental groups were performed by ANOVA
using Tukey tests. Statistical signiﬁcance was accepted at P<0.05.

2.8. Histopathological investigations

For histopathological examinations, rats were euthanized using diethyl ether and
tissue samples from liver and kidney were chopped and preserved in 10% formalin. After
two days, the formalin was changed, and the samples were processed for
histopathological staining. After parafﬁn embedding and block making, the tissue
sections were prepared with the hematoxylin-eosin staining method and were examined
under a light microscope (Olympus Optical Co., Tokyo, Japan) at 40x magnification.
3. Results and Discussion
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Figure 2. Cartoon representation of the morphology and content of the Pluronic
microemulsions used in the current study.
3.1. Determination of Microemulsion Formation Behavior
The microemulsions were synthesized by mixing the Pluronic polymer with a
solution of MTX, dissolved in ethyl butyrate as the “oil” phase, and fatty acids as the
surfactant (Figure 1). We started by investigating the dynamic behaviour of the F127based oil-in-water microemulsions as a function of the mass fraction of the nanodroplet
(MFD). The auto-correlation function of the microemulsions versus time for different
MFD values was plotted (Fig. 3a). The decay rate is, as expected, directly proportional to
the MFD; inter-droplet repulsive interactions increase as the number of droplets increases.
At a constant MTX concentration, more particles will mean a greater surface area is
available to host the MTX at the oil-water interface rather than being enclosed in the core
of the particles. The charged carboxylates on the water-facing MTX molecules induces a
charge density on the surface of the particle, leading to an increase in repulsion as has
been noted by us and others.[6, 17, 46, 47] From the experimental diffusion data, the
hydrodynamic diameters of the MTX -loaded microemulsions were obtained as a function
of MFD and demonstrated that size is inversely proportional to MFD. This further
supports the observation that surface area increases as the MFD increases due to the
reduction in particle clustering, consistent with the reports of others in similar systems
(Fig.3b). In other words, an enhancement of the electrostatic repulsion between
nanodroplets as the MFD increases (as more nanodroplets leads to a greater possibility of
inter-nanodroplet interactions) can lead to a reduction in the nanodroplet size. This occurs
because the PEO layer collapses inwards due to this effect. [1, 10, 17, 46] However, the
changes are small. In all cases, the average size of the particles is under 10 nm, and there
9

is likely little clinical difference between these various formulations. For this reason, the
particular formulation is unlikely a critical factor, and an MFD of 0.01 was selected as
the basis for the materials used in the other studies outlined here as it uses the minimum
amount of material, limiting off-target effects arising from the Pluronic polymer.
Although particle size plays a key role in nanobiointeractions in the physiological
milieu, as well as in particle biodistribution, targeting, cell uptake and internalization,
toxicity, and particle degradation; we want to stress that the size ranges of our
nanodroplets, 5-9 nm, is limited, and renal excretion is still readily possible for all of the
microemulsions studied here.

Figure 3. Dynamic light scattering behaviour as a function of MFD. A) Auto-correlation
function of microemulsions versus time for different MFD values (inset: decay rate vs MFD);
B) Hydrodynamic diameter as a function of MFD (inset: the Diffusion Coefficient versus MFD
for microemulsions); C) Digital photograph of the microemulsion solution after standing for 6
months.

3.2. Entrapment Efficiency
Ideally, as with any pharmaceutical intervention, the lowest possible dose of all
components of the formulation are desired. As the MTX dosage is the limiting factor,
we want to maximize the encapsulation efficiency of the nanocarrier to minimize the
amount of nanocarrier that must be used. This is determined by the entrapment
efficiency (EE%). The components of the formulation were selected to maximize this
parameter: high loading was predicted to be facilitated due to the molecular interactions
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between MTX and F-127. Using sodium caprylate as the surfactant further reduces
inadvertent burst release as it helps to rigidify the outer walls of the nanoparticles due to
its favorable apparent packing factor [48] coupled with the higher oil/water interface
area on the surface of the particles [49]. These factors, along with favorable economics,
are the reasons that it is commonly used as a surfactant for stabilizing microemulsions
[50]. In the EE% study, 320 nm absorption wavelength was chosen to avoid interfering
of polymeric backbones in UV-Vis spectrum of free MTX. In this case, loading the
MTX into the MFD 0.01 formulation described above resulted in a good EE % of 73.0
% ± 8.4 [57]. With the loading established, the stability of the microemulsion was
investigated.

3.3. Stability of F127 microemulsion

To achieve a stable microemulsion, one must incorporate a repulsion mechanism
that counteracts thermodynamically favourable Ostwald ripening. Such phenomenon
arises from the mutual attraction of particles and the decrease in energy that results from
the minimization of the surface area: volume ratio. This can be accomplished using either
electrostatic or steric repulsion. The former results from the incorporation of a double
layer of charged components in the particle’s shell; the latter is achieved by incorporating
non-ionic surfactants or polymers that interfere with membrane fusion. Steric repulsion
is very useful for preventing aggregation of colloidal solutions. As is usual, our
formulations combine both strategies as the caprylate provides a negative surface, while
the hydrocarbon chains of the Pluronic provide the steric blocking. Upon standing for
three months, no visible turbidity or sedimentation was observed (Figure 3c), suggesting
that no meaningful aggregation was observed. Similarly, the zeta potential of
microemulsion immediately after preparation and after three months remained similar:
they were -35 mV and -30 mV, respectively. Many authors have reported similar results:
the Pluronic polymers and their mutual steric repulsion defines the high stability of these
systems.[1, 5, 17, 20, 50] The size distribution of the materials also remained stable over
12 months; average particle size remained the same, and the dispersity index (PDI) only
11

changed from 0.21 to 0.26. This is consistent with similar F127 microemulsions from our
research group which were also completely stable for very long periods of time.[5]

3.4. Antioxidant activity of MTX-loaded microemulsion
MTX induces oxidative stress by interrupting the folate pathway, but is itself an
antioxidant. To quantify the relative antioxidant activity of the nanoformulations as a
proxy for exposed MTX, we employed the standard 2,2-diphenyl-1-picrylhydrazyl assay
in which the colour of a methanolic DPPH solution changes from purple to yellow. The
challenges in using this assay for predicting absolute antioxidative activity are many, and
it is not a precise tool; however, under proper control, it can be used to estimate the
relative behaviour of systems.[51, 52] We measured the reaction rate of the DPPH free
radical with both bulk and microemulsion forms of MTX (final concentration of 80
µg/ml). Under parallel measurements, initial reaction rates of 0.873 and 0.238 μg/ml ×
min were respectively measured for both the bulk solution and the microemulsion. This
approximate four-fold difference demonstrates that the microemulsion protects the drug
from metabolism and keeps it encapsulated. As it is located at the surface, some reactivity
is to be expected.

3.5. In vivo toxicity
Systemic MTX toxicity arises in the form of kidney or liver damage. Along with
histopathology, measuring the serum content of specific kidney and liver enzymes can
provide information about damage to these organs in an in vivo model.[53, 54] One of the
proposed benefits of microemulsions is protection from this toxicity: a formulated MTX
dose should be less toxic than a direct dissolved equivalent dose. To investigate toxicity,
ten healthy male Wistar rats were assigned to each of 5 groups. The first was a control
group on a saline; the others received intraperitoneal administration of a treatment. The
second received PBS, identical to the buffer used in the treatments. The third received the
F127 microemulsion without any MTX, the fourth received MTX in PBS (no
microemulsion) and the fifth received the formulated MTX. Liver enzyme levels (ALT
and AST) remained statistically unchanged for the PBS, F127 microemulsion, and MTX
(0.05 mg/kg)-microemulsion formulations (Fig. 4a and 4b). The 0.05 mg/kg direct
dissolved treatment did show a statistically significant increase in the enzyme levels
(P<0.05). The mean of the microemulsion is higher than the control, but the variance in
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the systems prevents it from reaching the threshold for significance. Serum BUN and
creatinine levels also followed the same exact pattern (Fig. 4c and 4d). Combined, these
results indicate that formulating MTX as a microemulsion renders the drug less toxic than
direct dissolution.
MTX-derived oxidative damage will occur outside of these organs and can be
measured by the upregulation of catalase to counteract the increased number of reactive
oxygen species. However, no significant increase in catalase activity was observed for
either MTX formulation (Fig. 4f). Curiously, the F127 microemulsion did elicit an
increase. Superoxide dismutase activity dropped in both the MTX-treated groups (Fig.
4e). This is possibly because MTX itself specifically interacts with ROS, decreasing the
need for enzyme upregulation. In contrast, malondialdehyde (MDA) levels were higher
in both MTX-treated groups. MDA is an excellent marker of the presence of ROS,
resulting directly from oxidative stress (Fig 4g). In both cases, the microemulsionformulated MTX moderated the effects, with the directly dissolved MTX showing greater
changes.
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Figure 4. Serum AST (A), AST (B), BUN (C), and creatinine (D) levels in male Wistar
rats, Mean ± SD, N=10. *P < 0.05, compared to the saline control group. Corrections
made for multiple comparisons. Enzyme levels in liver homogenates of SOD (E), catalase
(F), and MDA (G)

The histopathological observations align well with the biomarker measurements.
The livers of the rats who received saline, PBS, or MTX-free F127 microemulsion had a
normal hepatic architecture with distinct hepatocytes, central vein, and sinusoids (Fig. 5ac). Conversely, liver sections of rats treated with unformulated MTX (0.05 mg/kg; Figure
5d) showed signs of cell necrosis and a disarrangement of the sinusoids. The
administration of MTX microemulsion at a dose of 0.05 mg/kg (Fig 5e) caused no
pathological changes in liver sections compared to the rats not treated with MTX (Fig 5ac).
14

Figure 5. Liver sections stained by hematoxylin and eosin of rats: A) Saline; B) PBS; C)
F127 microemulsion with no MTX; D) MTX 0.05 mg/kg; E) MTX in microemulsion
formulated 0.05 mg/kg MTX. Alterations in liver tissue including congestion of central
vein (H), sinusoidal dilatation (arrow) are highlighted for the liver obtained from the liver
subjected to unformulated MTX. All images at 40x magnification.

There were similar changes in the kidney. Intraperitoneal injections of
unformulated MTX induced prominent histological changes in renal tissues, such as
decreased proximal tubule diameter (Fig. 6d), compared to healthy kidneys in the saline
control and the PBS and F127-treated groups (Fig. 6a-c). These same histopathological
changes were less prominent in the kidney micrographs of rats treated with the
microemulsion form of methotrexate (Fig. 6e); however, they are still present with clear
mild congestion of the proximal tubules.
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Figure 6. Rat kidney sections stained by hematoxylin and eosin: A) Saline; B) PBS; C)
F127 microemulsion no MTX; D) MTX 0.05 mg/kg; E) MTX in F127 0.05 mg/kg.
Congestion of proximal tubules is highlighted in both MTX-subjected kidneys using
arrows. 40x magnification was used for all images.

Rats subjected to the microemulsion-MTX suffered no hepatotoxic effects as
determined by the serum presence of elevated liver function biomarkers, or liver
histopathology. On the other hand, kidney histology was affected in the group treated
with the microemulsion forms of MTX. MTX is nephrotoxic, so the lower threshold on
this organ is to be expected.[55, 56] Unformulated MTX produced pronounced toxic
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effects on both the liver and the kidney according to both serum titres and histopathology.
Similar doses of MTX have shown similar nephrotoxicity, and hepatotoxicity.[57, 58]
Different MTX formulations have distinct biological activity, leading to the
development of a series of nanoemulsion delivery systems. The best-studied drug
delivery systems are solid-lipid nanoparticles, magnetic nanoparticles, carbon nanotubes,
human serum albumin, and polymeric nanoparticles.[59, 60] Since most of the studies
have been pre-clinical trials, at now, it is difficult to evaluate the benefits of one system
over the others. In the case of nano-emulsions synthesized in the present study, there is
still a lack of clinical trials to evaluate the advantages of methotrexate-loaded F127
microemulsions over other formulations. However, the laboratory animal models could
give us a better understanding of the newly formulated microemulsions.
experiments

have

been

conducted

on

biological

effects

of

Many

methotrexate

nanoformulations. The results of Mello and coworkers demonstrated that MTX-lipid
nanoemulsions at 0.2 mg/kg were effective intravenously.[61] MTX-microemulsions
based on Cremophore EL have also showed potent antitumor activities on prostate,
ovarian, and human breast carcinoma cell lines at 0.1 mg/mL and was more potent than
direct dissolution of the same concentration.[62]
The concentration tested in our study and our microemulsion formulation is
comparable to these systems. The results of this study clearly show that the
microemulsion formulation protects the rat from the off-target toxicity of MTX, and the
low cost and ease of synthesis of these F-127-based microemulsions might prove to make
them promising delivery formulations for both anti-cancer and anti-inflammatory
applications.

4. Conclusions
Encapsulation in oil-in-water microemulsions is well established to universally
improve the efficacy of MTX, but the effect on toxicity of these systems has not been
previously investigated in the literature. In this study, oil-in-water Pluronic F127-based
microemulsions containing the MTX drug were prepared at an equimolar oil-to-surfactant
molar ratio at nano-droplet mass fractions (MFD) of between 0.01 to 0.08. The droplet
size increased and the attractive interactions between nano-droplets increased as the MFD
rose. MTX encapsulation efficiency (EE%) of inside the microemulsions was ca. 73.0 %
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± 8.4 indicating a high loading of the drug into the nanocarrier. Finally, the
microemulsions remain stable for up to a year after synthesis, demonstrating their ability
to be stored long term and made in bulk.
F127-formulated MTX showed no liver toxicity, and only limited kidney toxicity
in comparison to an equivalent dose of the unformulated MTX in a Wistar rat model. This
formulation, and other similar approaches, is promising for the future of MTX clinical
deployment to improve outcomes for patients. However, measuring toxicity should be an
essential component of the study of chemotherapeutic microemulsions in this growing
literature.
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